Research programme: ocular inflammation therapy - Santen

Drug Profile

Research programme: ocular inflammation therapy - Santen

Alternative Names: Nova 22038

Latest Information Update: 29 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novagali Pharma
  • Developer Santen S.A.S.
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ocular inflammation

Most Recent Events

  • 29 May 2013 Discontinued - Preclinical for Ocular inflammation in France (Ophthalmic)
  • 25 Apr 2013 Novagali Pharma S.A.S. is now called Santen S.A.S.
  • 31 Jan 2012 Santen Pharmaceuticals acquires Novagali Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top